Analysts Set Zoetis Inc. (NYSE:ZTS) Price Target at $215.90

Zoetis Inc. (NYSE:ZTS) has received an average rating of “Buy” from the twelve brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $215.90.

A number of research analysts have recently commented on ZTS shares. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 over the last three months. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $30,000. Dunhill Financial LLC increased its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis during the 4th quarter worth approximately $44,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 2.5 %

Shares of NYSE:ZTS opened at $159.34 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The stock has a market cap of $71.35 billion, a price-to-earnings ratio of 29.13, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The firm’s 50 day moving average price is $166.04 and its 200 day moving average price is $173.88.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities research analysts predict that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.26%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.